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To determine clinical and virologic characteristics of 
pandemic (H1N1) 2009 in Buenos Aires, Argentina, we 
conducted real-time reverse transcription–PCR on samples 
from patients with inﬂ  uenza-like illness, June 11–30, 2009. 
Of 513 patients tested, 54% were positive for inﬂ  uenza virus 
subtype H1N1. Infection rate was lowest for patients ≥60 
years of age.
A 
novel inﬂ  uenza A (H1N1) virus emerged in mid-
April 2009 and spread rapidly among humans world-
wide (1,2). The virus, pandemic (H1N1) 2009 virus, is a 
unique combination of gene segments from North Ameri-
can and Eurasian swine lineages and ancestral genes de-
rived from avian species and humans (3,4). In Buenos 
Aires, Argentina, the ﬁ  rst laboratory-conﬁ  rmed case of 
pandemic (H1N1) 2009 was documented May 16, 2009, 
in a patient who had traveled to the United States. This in-
dex case seeded an elementary school outbreak in Buenos 
Aires, and, within days, several schools reported increas-
ing numbers of cases. The public health response included 
closure of schools with laboratory-conﬁ  rmed inﬂ  uenza 
subtype H1N1 cases, voluntary self-isolation and oselta-
mivir treatment of suspected and conﬁ  rmed patients, and 
recommended chemoprophylaxis for contacts. Despite 
these interventions, cases increased among the school-age 
and general population (5).
In early June, the number of conﬁ  rmed cases increased 
among young adults in Buenos Aires. In addition, cases 
more severe than those previously seen in school students 
were being identiﬁ  ed among young adults and pregnant 
women, some of whom required hospitalization in inten-
sive care units. On June 11, 2009, the World Health Orga-
nization declared a phase 6 pandemic of this subtype H1N1 
virus (6).
Argentina’s National Reference Laboratory (Instituto 
Nacional de Enfermedades Infecciosas, Administración 
Nacional de Laboratorios e Institutos de Salud, ANLIS, 
“Dr. Carlos G. Malbrán”) was initially designated as the 
only approved laboratory for diagnosing pandemic (H1N1) 
2009 virus infections. After the rapid increase in the num-
ber of cases and the elevation of the pandemic alert level, 
the virology laboratory at Centro de Educación Médica e 
Investigaciones Clínicas (CEMIC) University Hospital in 
Buenos Aires also began diagnosing infections. This report 
describes clinical and virologic ﬁ  ndings for the initial cases 
of pandemic (H1N1) 2009 diagnosed at CEMIC.
The Study
Study patients were enrolled from June 11 through 30, 
2009, a time that corresponds to the end of autumn and the 
beginning of winter in the southern hemisphere. Patients 
seeking care at CEMIC University Hospital and other 
healthcare providers in Buenos Aires (Federal District) 
were enrolled if they met the criteria for an inﬂ  uenza-like 
illness. During the study period, respiratory samples from 
513 patients were submitted to CEMIC’s virology labora-
tory for pandemic (H1N1) 2009 testing.
Combined nasal and pharyngeal swab specimens or 
nasopharyngeal or tracheal aspirates were obtained from 
patients and shipped to CEMIC in viral transport media. 
Epidemiologic and demographic parameters and informa-
tion on clinical signs, underlying disease, chest radiographs, 
and medication use were obtained for each patient.
A laboratory diagnosis of inﬂ  uenza infection was deter-
mined by real-time reverse transcription–PCR (RT-PCR), 
by using the Centers for Disease Control and Prevention’s 
protocol, on a Smart Cycler II (Cepheid, Sunnyvale, CA, 
USA) (7). The QIAamp Viral RNA Mini Kit (QIAGEN, 
Valencia, CA, USA) was used to extract RNA. Statisti-
cal analyses were performed by using χ2 and Fisher exact 
tests.
Of 513 patients, 275 (54%) had positive results for in-
ﬂ  uenza subtype H1N1 by RT-PCR (Table 1). Of these 275 
case-patients, 197 (72%) were outpatients and 78 (28%) 
were hospital inpatients. 
Pandemic (H1N1) 2009 was detected most frequently 
among patients <5 years of age (59%), followed by those 
19–59 years of age (57%). The lowest prevalence (37%) 
was among those >60 years of age; the difference in preva-
lence among those in this group and those in the groups <5 
and 19–59 years of age was signiﬁ  cant (p = 0.019 and p = 
0.003, respectively) (Table 1). The highest percentage of 
hospitalizations occurred among patients <5 years of age 
(51%), followed by those >60 years of age (36%). Among 
patients 19–59 years of age, 24% required hospitalization 
(Table 1).
The ﬁ  rst case-patient with pandemic (H1N1) 2009 
was admitted to CEMIC on June 4, 2009. The patient, 
a 29-year-old woman in week 36 of pregnancy, had no 
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within 24 hours of admission and for the next 33 days. 
During this period, 35 other case-patients with pandemic 
(H1N1) 2009 were hospitalized at CEMIC; of these 36 pa-
tients, 16 (44%) were admitted to the intensive care unit, 
and 10 (28%) required mechanical ventilation. The most 
common diagnosis for hospitalized patients was pneu-
monia; 42% had interstitial bilateral inﬁ  ltrates, 31% had 
focal consolidation, and 4% had pleural effusion. Chest 
radiographs were unremarkable for 23% of hospitalized 
patients. The mean hospital stay was 7 days (range 2–42 
days; median 9 days).
A total of 78 case-patients were hospitalized at CEMIC 
and other institutions in Buenos Aires. Six patients died, of 
whom 5 had an underlying condition: 3 were immunocom-
promised, 1 was obese and a chronic user of tobacco, and 1 
had pulmonary and heart disease. Three patients were >60 
years of age, 2 were in the 19–59-year age group, and 1 was 
an infant. Two hospitalized patients died at CEMIC. Both 
were >60 years of age, had underlying health conditions, 
and later developed bacterial sepsis; 1 also had bilateral 
pneumonia.
Underlying conditions were evaluated for all 275 pa-
tients with laboratory-conﬁ  rmed inﬂ  uenza virus subtype 
H1N1 infection. For evaluation, hospitalized and ambula-
tory patients were divided into 2 age groups: <5 and >5 
years of age. For patients >5 years of age, the presence of 
an underlying condition was signiﬁ  cantly associated with 
a higher rate of hospitalization (p = 0.040). Of the 78 hos-
pitalized patients, 56 (72%) had no underlying condition 
(Table 2).
Conclusions
From June 11–30, 2009, pandemic (H1N1) 2009 virus 
was detected in 54% of respiratory samples submitted to 
CEMIC’s virology laboratory. This percentage is similar 
to the overall percentage reported by Argentina’s National 
Reference Laboratory during the same period (8). How-
ever, initial reports from Mexico showed a lower positivity 
rate (29%, 2,582/8,817) (9). This difference may be part-
ly caused by the different clinical criteria for respiratory 
specimen collection, site restrictions, or seasonal factors. 
The percentage of inﬂ  uenza subtype H1N1 cases detected 
during this study (54%) is apparently higher than that for 
seasonal inﬂ  uenza A strains (H1N1 and H3N2) detected at 
CEMIC University Hospital during the same epidemiolog-
ic weeks in previous years (19% and 26% in children and 
adults, respectively, as conﬁ  rmed by immunoﬂ  uorescence 
testing) (10) (M. Echavarría, unpub. data).
The high frequency of infection with pandemic 
(H1N1) 2009 virus likely resulted from the lack of popu-
lation immunity to this antigenically novel H1N1 sub-
type. The lowest rate of infection was seen for patients 
>60 years of age. This ﬁ  nding may suggest that persons 
in this age group were previously exposed, through infec-
tion or vaccination, to an inﬂ  uenza A (H1N1) virus that 
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Table 1. Case-patients with pandemic (H1N1) 2009, by age group, CEMIC University Hospital, Buenos Aires, Argentina, June 11–30,
2009
Total case-patients*  Hospitalized case-patients  Case-patient
age, y 
No. (%) case-patients 
tested No. (%)†  95% CI‡  p value  No. (%)§  95% CI‡  p value 
<5 63 (12)  37 (59)  45.6–71.0 0.019 19 (51)  34.4–68.0 0.352
5–18 44 (9)  19 (43)  28.3–59.0 0.631 3 (16))  3.4–39.6 0.250
19–59 338 (66)  194 (57)  51.9–62.7 0.003 47 (24)  18.4–30.9 0.304
>60¶ 68 (13)  25 (37)  25.4–49.3 — 9 (36)  17.9–57.4 —
Total 513 (100)  275 (54)  49.2–58.0 — 78 (28)  23.1–34.1 —
*Patients with subtype H1N1 infection confirmed by real-time reverse transcription–PCR. 
†Percent of all patients tested. 
‡CI, confidence interval. 
§Percent of all patients with influenza virus subtype H1N1 infection. 
¶Reference group. 
Table 2. Underlying clinical conditions in 275 case-patients with pandemic (H1N1) 2009, by age group, CEMIC University Hospital,
Buenos Aires, Argentina, June 11–30, 2009  
Case-patients <5 y of age  Case-patients >5 y of age  
Clinical condition  
No. (%) 
hospitalized
No. (%) 
outpatients p value 
No. (%) 
hospitalized
No. (%) 
outpatients p value 
None* 15 (79)   16 (89)  —  41 (69)   148 (83)  —
Underlying condition  4 (21)   2 (11) 0.659 18 (31)   31 (17)  0.040
Immunocompromised  1 (5)   1 (5.5)  0.999 9 (15)   11 (6)  0.028
Pregnant 0 0 —  1 (2)   4 (2)  0.999
Other†  3 (16)   1 (5.5)  0.603 8 (14)   16 (9)  0.205
Total 19  18  —  59   179  —
*Reference group. 
†Hematologic malignancies, chronic lung disease (asthma, chronic obstructive pulmonary disease), chronic cardiac disease, diabetes and obesity. Pandemic (H1N1) 2009, Buenos Aires
is genetically and antigenically more closely related to 
pandemic (H1N1) 2009 than to other recent inﬂ  uenza A 
viruses (11).
Our  ﬁ  nding that 66% of respiratory samples tested 
during this study were from patients 19–59 years of age 
is similar to ﬁ  ndings in previous pandemic inﬂ  uenza situ-
ations. Furthermore, 49% of hospitalized patients in this 
study were 19–59 years of age. Most case-patients hospital-
ized with pandemic (H1N1) 2009 infection (72%) had no 
underlying medical condition, but a severe degree of lung 
involvement was observed in these patients: one third re-
quired mechanical ventilation support.
We report a mortality rate of 2% among the 275 con-
ﬁ  rmed pandemic (H1N1) 2009 case-patients followed in 
this study. A similar rate (2.3%) was reported by the Na-
tional Ministry of Health during the same period (8). From 
May through December 4, 2009, a total of 11,234 cases 
were conﬁ  rmed in Argentina, and 613 (5.5%) case-patients 
died (5). In the Americas, Argentina currently has the 
fourth highest number of deaths associated with inﬂ  uenza 
virus subtype H1N1, after the United States, Brazil, and 
Mexico (12). The reasons for these unusual epidemiologic 
features are the focus of ongoing investigations.
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